Euroopan unioni -
suomi -
EMA (European Medicines Agency)
rybrevant
janssen-cilag international n.v. - amivantamab - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
lidbree 42 mg/ml geeli kohtuun
gedeon richter plc - lidocaine - geeli kohtuun - 42 mg/ml - lidokaiini
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
dimethyl fumarate accord
accord healthcare s.l.u. - dimetyylifumaraatti - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressantit - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
hyftor
plusultra pharma gmbh - sirolimuusin - angiofibroma; tuberous sclerosis - hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.
